CorVel Corporation — Form 10-Q Summary
Period clarification: The filing covers the three months ended June 30, 2013, CorVel’s first quarter of fiscal 2014, and compares results with the three months ended June 30, 2012. This differs from the “2012 Q1” period in the request metadata.
Business context
CorVel provides workers’ compensation and auto medical-cost containment and managed-care services, including patient management and network solutions. It reports one operating segment. Patient management accounted for 51.9% of quarterly revenue, up from 50.3%; network solutions accounted for 48.1%, down from 49.7%.
Financial performance
| Metric | Quarter ended June 30, 2012 | Quarter ended June 30, 2013 | Change |
|---|---|---|---|
| Revenue | $104.6 million | $118.1 million | +12.9% |
| Cost of revenue | $81.4 million | $91.2 million | +12.0% |
| Gross profit / margin | $23.2 million / 22.2% | $26.9 million / 22.8% | +16.1% gross profit |
| General and administrative expense | $12.2 million | $12.8 million | +5.5% |
| Income before taxes / margin | $11.0 million / 10.5% | $14.1 million / 11.9% | +27.9% |
| Net income | $6.6 million | $8.6 million | +30.5% |
| Diluted EPS | $0.29 | $0.40 | +37.9% |
| Operating cash flow | $13.5 million | $16.8 million | +$3.3 million |
Cash and equivalents were $25.0 million at June 30, 2013, versus $19.8 million at March 31, 2013. Working capital was $39.4 million, down from $40.1 million. The company reported no debt and no revolving borrowings. Its credit facility provides up to $10 million, but expires in September 2013; $8.0 million of letters of credit were outstanding and do not reduce facility availability. Capital expenditures were $5.5 million, including costs related to a new data center and a software-license financing arrangement. Treasury-stock purchases used $7.3 million of cash.
Changes and management commentary
- Revenue growth was primarily driven by patient management, including services to TPA customers, which increased 32% year over year; network solutions revenue rose 9.3%, primarily on pharmacy services.
- Management attributed higher cost of revenue to the shift toward lower-margin services, labor needs for TPA customers, and increased prescription-processing volume. It cited emerging economies of scale in TPA services.
- Management expects TPA revenue to continue growing, but cautioned that margins could decline unless the company improves efficiency, raises prices, or grows higher-margin services.
- G&A expense increased mainly because of higher legal costs. The effective tax rate was 39%, compared with 40%, with the decrease primarily attributed to a retroactively extended tax credit.
- Weighted-average diluted shares fell 5.5%, primarily because of share repurchases. The board declared a two-for-one stock split during the quarter; reported historical share and per-share figures were adjusted retroactively.
Liquidity, outlook, risks, and unusual items
Management said cash, operating cash flow, and expected option-exercise proceeds should be sufficient to fund obligations, planned repurchases, new services, and business development for at least the next 12 months. No specific revenue or earnings guidance was provided. Quarterly results are not necessarily indicative of full-year results.
Contractual obligations totaled $48.8 million, including $45.6 million of operating leases, $2.3 million of software-license obligations, and $0.9 million of uncertain tax positions. Unrecognized tax benefits were $869,000. Management said ordinary-course litigation was not expected to result in aggregate material payments. The filing also describes estimation risks involving revenue recognition, receivables, self-insurance, taxes, contingencies, stock compensation, and software costs.
Key disclosed risks include lower workers’ compensation claim volumes, customer insourcing or contract losses, competition and pricing pressure, labor availability and costs, regulatory changes, legal exposure, cybersecurity and data-processing interruptions, and the ability to develop and implement technology. Subsequent to quarter-end through July 24, CorVel repurchased 125,293 shares for $3.9 million, averaging $30.98 per share. Disclosure controls were deemed effective, with no material change in internal control reported.
Important facts for investors to verify
- Whether TPA-led growth can produce adequate margins as labor-intensive services expand.
- Renewal or replacement of the $10 million credit facility before its September 2013 expiration.
- Cash generation and capital needs after repurchases, data-center spending, and software-license payments.
- Trends in workers’ compensation claims, customer retention, and demand for outsourced managed-care services.
- Potential developments in litigation, uncertain tax positions, and self-insurance estimates.